Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1][1]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and has set a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the class action [1]. - The lawsuit claims that Vistagen and its executives violated federal securities laws by failing to disclose material adverse facts about the drug fasedienol's trial results [1][1]. - Following the announcement of the failed PALISADE-3 clinical trial results, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [1][1]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen reported that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in reducing anxiety compared to placebo [1][1]. - The positive assertions made by Vistagen regarding fasedienol's future trial success were deemed false and misleading, contributing to the inflated stock prices prior to the announcement [1][1]. Group 3: Investor Information - Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1][1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [1][1].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Shareholders that lost money on Vistagen Therapeutics, Inc.(VTGN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of misleading statements regarding the company's clinical trial results, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Vistagen - The complaint alleges that Vistagen and its executives violated federal securities laws by making false and misleading statements about the likelihood of success for the fasedienol drug based on previous clinical trial results [4]. - The announcement on December 17, 2025, revealed that the PALISADE-3 study did not meet its primary efficacy endpoint, causing Vistagen's stock price to plummet over 81% to $0.88 per share [5].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Vistagen and cer ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 clinical trial [5][6]. - The defendants made positive assertions about the drug's trial success based on previous results, which the lawsuit claims were misleading [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of securities law violations related to misleading statements about the company's clinical trial results for fasedienol, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights and options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false and misleading statements regarding the likelihood of success in the PALISADE-3 clinical trial, which misled investors and inflated stock prices [4]. Group 2: Clinical Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share [5]. - The study did not show statistically significant improvement in reducing anxiety compared to placebo, which contradicted earlier positive assertions made by the company [4][5]. Group 3: Firm Background and Recovery - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 clinical trial [5][6]. - The defendants made positive assertions about the drug's trial success based on previous results, which the lawsuit claims were misleading [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4] Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5] - Defendants reportedly made overly positive statements about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6]